Huber, Rudolf M

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 1,415

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry

Behr, J., Kreuter, M., Hoeper, M. M., Wirtz, H., Klotsche, J., Koschel, D., Andreas, S., Claussen, M., Grohé, C., Wilkens, H., et al. (2015) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 247